PharmaLogic Holdings Corp. announced Nov. 9 that it has signed a definitive agreement to acquire Lantheus Holdings Inc.’s contract development and manufacturing organization business and its manufacturing facility in Springfield, New Jersey. Financial terms were not released. The transaction remains subject to regulatory review and customary closing requirements, and the companies will continue operating separately until it closes.
What it means
After closing, the Springfield facility’s workforce will become part of Agilera, PharmaLogic’s therapeutic CDMO business. The agreement also provides for a long-term arrangement under which Agilera will produce lutetium Lu 177 dotatate for Lantheus.
PharmaLogic said the acquisition will increase its U.S. manufacturing capacity for radiopharmaceutical therapeutics. The company said the transaction will make it the first therapeutic CDMO with a transatlantic platform.
Key facts
- PharmaLogic announced the agreement on Nov. 9, 2026.
- The acquisition covers Lantheus’ CDMO business and Springfield, New Jersey manufacturing facility.
- Financial terms were not disclosed.
- Agilera has more than 15 years of experience supporting radioligand therapies.
- Agilera supplies an alpha therapy in more than 30 countries.
- PharmaLogic operates a network of more than 45 facilities across the U.S., Puerto Rico, Canada and Norway, according to the company.
- Leerink Partners advised PharmaLogic financially, while Goodwin Procter LLP served as legal adviser.
- Solomon Partners Securities LLC advised Lantheus financially, and Covington & Burling LLP served as legal adviser.
Source: PharmaLogic Holdings Corp. news release (PR Newswire)